Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
55.24
+0.16 (0.29%)
Jan 8, 2025, 4:00 PM EST - Market closed
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TARS stock have an average target of 54.2, with a low estimate of 41 and a high estimate of 65. The average target predicts a decrease of -1.88% from the current stock price of 55.24.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 15, 2024.
Analyst Ratings
The average analyst rating for TARS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $41 | Hold | Maintains | $36 → $41 | -25.78% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $63 → $65 | Buy | Maintains | $63 → $65 | +17.67% | Nov 14, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $61 → $63 | Buy | Reiterates | $61 → $63 | +14.05% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $61 | Strong Buy | Maintains | $57 → $61 | +10.43% | May 13, 2024 |
| Barclays | Barclays | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +8.62% | May 10, 2024 |
Financial Forecast
Revenue This Year
177.16M
from 17.45M
Increased by 915.42%
Revenue Next Year
313.52M
from 177.16M
Increased by 76.97%
EPS This Year
-3.31
from -4.62
EPS Next Year
-1.84
from -3.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 184.8M | 366.3M | 583.2M | |||
| Avg | 177.2M | 313.5M | 507.1M | |||
| Low | 167.6M | 270.6M | 408.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 959.3% | 106.8% | 86.0% | |||
| Avg | 915.4% | 77.0% | 61.7% | |||
| Low | 860.5% | 52.7% | 30.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.13 | -1.00 | 3.64 |
| Avg | -3.31 | -1.84 | 1.95 |
| Low | -3.36 | -3.40 | 0.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.